LUMIFYDrops.com/Professional
`
`See the Results
`Real results from real people, no retouching.†
`
`BRIMONIDINE TARTRATE OPHTHALMIC SOLUTION 0.025%
`REDNESS RELIEVER EYE DROPS
`
`BEFORE
`
`AFTER
`
`A REDNESS RELIEVER LIKE NO OTHER
`
`Representative of mean score pre-instillation: 1.8
`
`Representative of mean score 5-minute post-instillation: 0.5
`
`*Simulation to reflect average clinical trial results.
`
`FDA
`APPROVED
`
`The first and only OTC eye drop with
`low dose brimonidine tartrate (0.025%)
`
`Strong safety and efficacy profile
`with low risk for rebound hyperemia
`or tachyphylaxis in clinical trials
`
`Starts working within 1 minute –
`lasts for up to 8 hours
`
`1MIN
`
`8HOURS
`
`79% maintained
`95% reported
`significant redness
`significant improvement
`reduction at 8 hours†
`in just 1 minute†
`†Based on patient reported findings from Phase 3.
`
`Patient Satisfaction*
`
`are satisfied with LUMIFY
`eye drops overall
`
`agree that LUMIFY dramatically
`reduces redness
`
`say LUMIFY eye drops feel
`soothing and refreshing
`
`95
`92
`92
`
`%% %
`
`*source: according to an In Home Use Test survey conducted in March, 2018 (n=301)
`
`How to Order LUMIFY
`to Sell in Your Office
`Call 1-800-828-9030 to set up an account
`and receive supplied application to fill out.
`7.5mL size available; 1 case minimum
`Suggested Retail Price: $25.99
`
`For professional samples, call:
`1-833-4-LUMIFY (1-833-458-6439)
`
`Learn more at
`LUMIFYDrops.com/Professional
`Visit our website for the MOA video,
`downloadable resources, upcoming professional
`events, videos and so much more!
`
`LUMIFY is a trademark of Bausch & Lomb Incorporated or its affiliates.
`© 2021 Bausch & Lomb Incorporated or its affiliates. LUM.1827.USA.21
`
`†1 drop administered.
`After image taken 5 minutes past-instillation.
`
`Eye Therapies Exhibit 2055, 1 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`

`

`A unique method of action for reducing eye redness
`LUMIFY is the only OTC redness reliever that primarily constricts the venule.
`
`Other OTC redness relievers
`(α1 or α1/α2-AR agonist)
`
`Commonly associated with
`rebound redness and tachyphylaxis
`
`Non-selective vasoconstrictors
`act on the arteriole, decreasing
`blood and oxygen flow to
`surrounding tissue.
`
`LUMIFY with low dose brimonidine
`tartrate (selective α2-AR agonist)
`
`No tachyphylaxis and virtually
`no rebound redness in clinical trials
`when used as directed
`
`LUMIFY selectively constricts
`the venule, alleviating the potential
`decrease of blood and oxygen flow
`to surrounding tissue.
`
`Overall, six clinical studies were conducted in over 600 patients to evaluate safety
`and efficacy, with no evidence of allergic reactions reported.
`
`Low incidence of tachyphylaxis or rebound hyperemia1
`Phase III efficacy study2:
`
`Recommend LUMIFY eye drops today! LUMIFYDrops.com/Professional
`
`Top Frequently Asked Questions
`
`What concentration of benzalkonium chloride (BAK)
` preservative is in LUMIFY?
`The majority of commercially available topical eye drops contain BAK.
` The concentration of BAK in LUMIFY is 0.01%, which is lower than the
` maximum 0.02% allowed by the FDA.
`
`Were there any incidences of allergic reaction to low dose
`brimonidine tartrate?
`No evidence of allergic reaction to LUMIFY was reported in clinical trials.
`
`How will LUMIFY affect pupil dilation?
`In clinical studies, LUMIFY had no impact on pupil dilation. LUMIFY
`does not have this warning on its label like many other redness relievers.
`
`Was there an intraocular pressure (IOP) lowering effect?
`In phase 3 clinical studies there was no statistically significant evidence
`of IOP lowering.
`
`See How LUMIFY works differently
`
`1 McLaurin E, Cavet ME, Gomes PJ, Ciolino JB. Brimonidine ophthalmic solution 0.025% for reduction of ocular redness: A randomized clinical trial. Optom Vis Sci. 2018;95(3):264-271
`2 Phase III was a double-blinded, randomized, placebo controlled study. n=60.
`* P<0.0001 between visit 1 and visit 2; P<0.0005 between visit 2 and visit 3; Dosage = 1 drop in both eyes QID.
`
`Other traditional redness relievers
`
`LUMIFY redness reliever with low-dose Brimonidine
`
`Eye Therapies Exhibit 2055, 2 of 2
`Slayback v. Eye Therapies - IPR2022-00142
`
`